Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rostafuroxin dose comparison versus losartan in genetically selected adults with essential hypertension
2010-022073-34Phase 2Completed
- Sponsor
- CVie Therapeutics
- Start
- Dec 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rostafuroxin and losartan in hypertension (HTN) (4 arms), sponsored by CVie Therapeutics. Primary endpoint: Change from baseline to Visit 6 in office sitting systolic blood pressure. Started Dec 2010; status: completed.
02
Drugs
rostafuroxinlosartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2010-022073-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022073-34.